

Bölüm 22

NÖROENDOKRİN TÜMÖR METASTAZLARI VE GÜNCEL CERRAHİ TEDAVİ SEÇENEKLERİ

Abdulcabbar KARTAL²⁴

GİRİŞ

Nöroendokrin tümörler (NET), heterojen bir neoplazm türüdür. Bu tümörlerin nöroendokrin hücrelerden ve vücutta bulunan nöroendokrin hücre öncüllerinden ortaya çıktığı düşünülmektedir. Bu tümör grubunun farklı biyolojik davranışları olabilmektedir. Peptid salınımı ile farklı hormonal sendromlara neden olabilmeye özelliklerine göre de ayırt edilebilirler. Histolojik özelliklerine göre sınıflandırılan bu tümörler vücut için farklı bölgelerde ortaya çıkabilir (Tablo 1). Sınıflandırmada tümörler temel olarak iki kategoriye ayrılabilir. Bu sınıflandırmaya göre NET'ler nispeten selim, iyi diferansiye, karsinoid tümör ve pankreatik nöroendokrin tümör gibi davranan tümörler ile habis özellik gösteren az diferansiye ve akciğerin küçük hücreli karsinomu gibi davranan tümörler olarak iki ana kategoriye ayrılabilir (1-2).

Tablo 1. Başlıca NET özellikleri

En sık NET yerleşimleri	Sık salgılanan hormonlar	Başlıca klinik belirtiler
Mide	Serotonin	İshal
İnce barsaklar	Histamin	Deride ve yüzde kızarma
Apendiks	Bradikinin	Mide ve karın ağrısı
Kolon ve rektum		Kalp sorunları (çarpıntı)
Pankreas		Hırıltı ve nefes darlığı

²⁴ Dr. Öğretim Üyesi İstanbul Okan Üniversitesi Tıp Fakültesi Genel Cerrahi Anabilim Dalı abdulcabbar.kartal@okan.edu.tr, narcabb@gmail.com

KAYNAKLAR

1. Ferhatoğlu MF, Kartal A, Kivılcım T. Gastrointestinal stromal tumor mimicking such as incarcerated inguinal hernia. *Medical Science and Discovery*. 2018; 5(3):166-8. DOI:10.17546/msd.407478.
2. Panzuto F, Boninsegna L, Fazio N, et al. Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. *J Clin Oncol* 2011;29:2372-2377.
3. Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the ORDIC NEC study. *Ann Oncol* 2013;24:152-160.
4. Chagpar R, Chiang YJ, Xing Y, et al. Neuroendocrine tumors of the colon and rectum: prognostic relevance and comparative performance of current staging systems. *Ann Surg Oncol* 2013;20:1170-1178.
5. Kim HS, Lee HS, Nam KH, et al. p27 Loss Is Associated with Poor Prognosis in astroenteropancreatic Neuroendocrine Tumors. *Cancer Res Treat* 2014;46:383-392.
6. Haug AR, Cindea-Drimus R, Auernhammer CJ, et al. Neuroendocrine tumor recurrence: diagnosis with 68Ga-DOTATATE PET/CT. *Radiology* 2014;270:517-525.
7. Saund MS, Al Natour RH, Sharma AM, et al. Tumor size and depth predict rate of lymph node metastasis and utilization of lymph node sampling in surgically managed gastric carcinoids. *Ann Surg Oncol* 2011;18:2826-2832.
8. Moertel CG, Weiland LH, Nagorney DM, Dockerty MB. Carcinoid tumor of the appendix: treatment and prognosis. *N Engl J Med* 1987;317:1699-1701.
9. Mullen JT, Savarese DM. Carcinoid tumors of the appendix: a population-based study. *J Surg Oncol* 2011;104:41-44.
10. Sandor A, Modlin IM. A retrospective analysis of 1570 appendiceal carcinoids. *Am J Gastroenterol* 1998;93:422-428
11. Coskun H, Bostanci O, Dilege ME, et al. Carcinoid tumors of appendix: treatment and outcome. *Ulus Travma Acil Cerrahi Derg* 2006;12:150-154.
12. Cwikla JB, Buscombe JR, Caplin ME, et al. Diagnostic imaging of carcinoid metastases to the abdomen and pelvis. *Med Sci Monit* 2004;10 Suppl 3:9-16.
13. Glazer ES, Tseng JF, Al-Refai W, et al. Long-term survival after surgical management of neuroendocrine hepatic metastases. *HPB (Oxford)* 2011;12:427-433.
14. Lesurtel M, Nagorney DM, Mazzaferro V, et al. When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations. *HPB (Oxford)* 2015;17:17-22.
15. Mayo SC, de Jong MC, Pulitano C, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. *Ann Surg Oncol* 2010;17:3129-3136.
16. Saxena A, Chua TC, Perera M, et al. Surgical resection of hepatic metastases from neuroendocrine neoplasms: a systematic review. *Surg Oncol* 2012;21:e131-141.
17. Johnston FM, Mavros MN, Herman JM, Pawlik TM. Local therapies for hepatic metastases. *J Natl Compr Canc Netw* 2013;11:153-160.
18. Jones NB, Shah MH, Bloomston M. Liver-directed therapies in patients with advanced Neuroendocrine tumors. *J Natl Compr Canc Netw* 2012;10:765-774.
19. Kennedy A, Bester L, Salem R, et al. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference. *HPB (Oxford)* 2015;17:29-37.
20. Du S, Ni J, Weng L, et al. Aggressive Locoregional Treatment Improves the Outcome of Liver Metastases from Grade 3 Gastroenteropancreatic Neuroendocrine Tumors. *Medicine (Baltimore)* 2015;94:e1429.

21. Liu DM, Kennedy A, Turner D, et al. Minimally invasive techniques in management of hepatic neuroendocrine metastatic disease. *Am J Clin Oncol* 2009;32:200-215.
22. Bonaccorsi-Riani E, Apestegui C, Jouret-Mourin A, et al. Liver transplantation and neuroendocrine tumors: lessons from a single centre experience and from the literature review. *Transpl Int* 2010;23:668-678.
23. Gedaly R, Daily MF, Davenport D, et al. Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database. *Arch Surg* 2011;146:953-958.
24. Lehnert T. Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. *Transplantation* 1998;66:1307-1312.
25. Le Treut YP, Gregoire E, Belghiti J, et al. Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: an 85- case French multicentric report. *Am J Transplant* 2008;8:1205-1213.
26. Le Treut YP, Gregoire E, Klempnauer J, et al. Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study. *Ann Surg* 2013;257:807-815.
27. Rosenau J, Bahr MJ, von Wasielewski R, et al. Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors. *Transplantation* 2002;73:386-394.
28. Rossi RE, Burroughs AK, Caplin ME. Liver transplantation for unresectable neuroendocrine tumor liver metastases. *Ann Surg Oncol* 2014;21:2398-2405.
29. Tsutsumi K, Ohtsuka T, Mori Y, et al. Analysis of lymph node metastasis in pancreatic neuroendocrine tumors (PNETs) based on the tumor size and hormonal production. *J Gastroenterol* 2012;47:678-685.
30. Boninsegna L, Panzuto F, Partelli S, et al. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. *Eur J Cancer* 2012;48:1608-1615.
31. De Jong MC, Farnell MB, Sclabas G, et al. Liver-directed therapy for hepatic metastases in patients undergoing pancreaticoduodenectomy: a dual-center analysis. *Ann Surg* 2010;252:142-148.
32. Kulke MH, Siu LL, Tepper JE, et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. *J Clin Oncol* 2011;29:934-943.
33. Mazzaferro V, Pulvirenti A, Coppa J. Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation? *J Hepatol* 2007; 47:460-466.
34. Máthé Z, Tagkalos E, Paul A, et al. Liver transplantation for hepatic metastases of neuroendocrine pancreatic tumors: a survival-based analysis. *Transplantation* 2011; 91:575.
35. https://www.nccn.org/professionals/physician_gls/default.aspx (Accessed on April 23, 2019).
36. <https://www.uptodate.com/contents/metastatic-gastroenteropancreatic-neuroendocrine-tumors-local-options-to-control-tumor-growth-and-symptoms-of-hormone>. Hypersecretion?source=autocomplete&index=2~3&search=carc
37. Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? *J Am Coll Surg* 2000; 190:432.
38. Elias D, Lasser P, Ducreux M, et al. Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. *Surgery* 2003; 133:375.
39. Sarmiento JM, Heywood G, Rubin J, et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. *J Am Coll Surg* 2003; 197:29.
40. Osborne DA, Zervos EE, Strosberg J, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. *Ann Surg Oncol* 2006; 13:572.

41. Ahmed A, Turner G, King B, et al. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. *Endocr Relat Cancer* 2009; 16:885.
42. Glazer ES, Tseng JF, Al-Refaie W, et al. Long-term survival after surgical management of neuroendocrine hepatic metastases. *HPB (Oxford)* 2010; 12:427.
43. Mayo SC, de Jong MC, Pulitano C, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. *Ann Surg Oncol* 2010; 17:3129.
44. Saxena A, Chua TC, Sarkar A, et al., Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach. *Surgery* 2011; 149:209.
45. mGaujoux S, Gonen M, Tang L, et al. Synchronous resection of primary and liver metastases for neuroendocrine tumors. *Ann Surg Oncol* 2012; 19:4270.
46. Bagante F, Spolverato G, Merath K, et al. Neuroendocrine liver metastases: The chance to be cured after liver surgery. *J Surg Oncol* 2017; 115:679.
47. Righi L, Gatti G, Volante M, Papotti M. Lung neuroendocrine tumors: pathological characteristics. *J Thorac Dis* 2017;9:1442-1447.
48. Travis WD, Brambilla EW, Burke AP, et al. WHO Classification of Tumours of the Lung, Pleura, Thymus, and Heart, IARC Press, Lyon 2015.
49. Travis, WD.. The concept of pulmonary neuroendocrine tumours.. In: *Pathology & Genetics: Tumours of the Lung, Pleura, Thymus, and Heart.*, Travis, WD, Brambilla, E, Muller-Hermelink, HK, Harris, CC. (Eds), IARC Press, Lyon 2004. p.19.
50. Travis WD, Linnoila RI, Tsokos MG, Hitchcock CL, Cutler GB Jr, Nieman L, Chrousos G, Pass H, Doppman J. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. *Am J Surg Pathol.* 1991 Jun;15(6):529-53.